Cabazitaxel, a taxane for men with hormone-refractory metastatic prostate cancer
Wilkes, G.M.
Oncology 24(10 Suppl): 46-48
2010
ISSN/ISBN: 0890-9091 PMID: 21275327 Document Number: 644549
Document emailed within 1 workday
Related Documents
Ecstein-Fraisse, E.; Su, Z. 2014: Cabazitaxel--a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(7): 817-822Coccaro, M.; Tartarone, A.; Romano, G.; Ardito, R.; Di Renzo, N. 2005: Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer Tumori 91(4): 314-316
Ngo, L.S.M.; Yeo, A.; Wong, A.S.C.; Tay, M.Hiang. 2007: Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore Annals of the Academy of Medicine Singapore 36(10): 811-814
Arena, F. 2008: Dutasteride in the treatment of hormone refractory prostate cancer Minerva Urologica e Nefrologica 60(2): 71-76
Roth, B.J. 1996: New therapeutic agents for hormone-refractory prostate cancer Seminars in Oncology 23(6 Suppl 14: 49-55
Ross, R.W.; Kantoff, P.W. 2007: Hormone-refractory prostate cancer: choosing the appropriate treatment option Oncology 21(2): 185-193; Discussion 194: 199-200
Dexeus, F.; Logothetis, C.J.; Samuels, M.L.; Hossan, E.; von Eschenbach, A.C. 1985: Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer Cancer Treatment Reports 69(7-8): 885-886
Fujinami, K.; Miura, T.; Takizawa, A.; Osada, Y. 2005: Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 51(1): 5-8
Yang, N-qin.; Wang, Y-xin. 2006: Current situation of researches on the molecule mechanism of hormone refractory prostate cancer Zhonghua Nan Ke Xue 12(6): 551-554
Kelly, W.K. 1998: Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer European Urology 34(Suppl): 18-23
Awakura, Y.; Yamamoto, M.; Fukuzawa, S.; Itoh, N.; Nonomura, M.; Fukuyama, T. 2000: Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 46(7): 449-452
Boehmer, A.; Anastasiadis, A.G.; Feyerabend, S.; Nagele, U.; Kuczyk, M.; Schilling, D.; Corvin, S.; Merseburger, A.S.; Stenzl, A. 2005: Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience Anticancer Research 25(6c): 4481-4486
Kawaguchi, T.; Mayama, I.; Iwabuchi, I.; Ogasawara, M.; Tsukui, A. 2010: Chemo-endocrine therapy with low-dose cisplatin, UFT, and dexamethasone for hormone-refractory prostate cancer patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(10): 1921-1925
Miglietta, L.; Cannobbio, L.; Boccardo, F. 1995: Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity Anticancer Research 15(6b): 2825-2828
Sinibaldi, V.J.; Carducci, M.; Laufer, M.; Eisenberger, M. 1999: Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer Seminars in Oncology 26(5 Suppl 17: 45-48
Colombel, M.; Davin, J.-L.; Filleul, A.; Rousseau, C. 2004: Diagnosis and management of advanced hormone-refractory prostate cancer: results of a practice survey on 301 French urologists Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 14(2): 182-188
Azuma, K.; Kawakami, K.; Yuasa, T.; Sugisaki, T.; Hashimoto, K.; Aoyama, T.; Suzuki, K.; Yonese, J.; Hama, T. 2018: Safety Profile of the Combination of Prophylactic Pegfilgrastim and Cabazitaxel for Japanese Patients with Castration Resistant Prostate Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(12): 1737-1742
Koutsilieris, M.; Reyes-Moreno, C.; Sourla, A.; Dimitriadou, V.; Choki, I. 1997: Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer Anticancer Research 17(3a): 1461-1465
Koyama, H.; Iesato, A.; Fukushima, Y.; Okada, T.; Watanabe, T.; Harada, M.; Ito, T.; Maeno, K.; Mochizuki, Y.; Ito, K.; Amano, J. 2011: A retrospective study of high-dose toremifene treatment for patients with aromatase inhibitor refractory advanced or metastatic hormone receptor-positive breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1123-1126
Hsieh, T-Chen.; Lu, X.; Guo, J.; Xiong, W.; Kunicki, J.; Darzynkiewicz, Z.; Wu, J.M. 2002: Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies International Journal of Oncology 20(4): 681-689